Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On November8, 2017, Intra-Cellular Therapies, Inc. (the “Company”) announced its financial results for the third quarter ended September30, 2017, and provided a corporate update.
A copy of the Company’s press release containing such announcements is attached hereto as Exhibit 99.1. The information in the press release set forth in the first four paragraphs under the heading “Third Quarter 2017 Financial Results,” together with the condensed consolidated financial information included in the press release, are incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.
In the press release dated November8, 2017, the Company also provided a corporate update. The information set forth in the last paragraph under the heading “Third Quarter 2017 Financial Results” and under the headings “Corporate Update” and “About Intra-Cellular Therapies,” together with the forward-looking statement disclaimer at the end of the press release, are incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.
|Item 2.02||Financial Statements and Exhibits.|
|99.1||Press release dated November8, 2017.|
The press release may contain hypertext links to information on our website. The information on our website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
The portions of the press release incorporated by reference into Item 2.02 of this Current Report on Form 8-K are being filed to Item 2.02. The remaining portions of the press release are being furnished to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Intra-Cellular Therapies, Inc. ExhibitEX-99.1 2 d489488dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update NEW YORK,…To view the full exhibit click
About Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.